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Despite the huge clinical success of antiretroviral therapy, several factors such as side effects, requirement of
life-long adherence, high cost, incomplete access to therapies and development of drug resistance make the quest
for an ultimate cure of HIV/AIDS a worldwide priority of biomedical research. In this respect, several sterilizing or
functional cures have been reported in the last years in both non-human primates and humans. This review
provides a summary of the main results achieved so far, outlining their strengths as well as their limitations. A synthetic
interpretation of these results could be pivotal in order to develop an effective and widely available cure.
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Introduction
The quest of a cure for AIDS has been defined a “hercu-
lean task” [1], given the enormous complexities behind
it and the numerous setbacks that have curbed early en-
thusiasms along the years. The ultimate goal of research
for a cure is the complete eradication of the virus from
the organism (i.e. a “sterilizing cure”), but a more feas-
ible goal may be the achievement of spontaneous drug-
free control of the infection without disease progression
(i.e. a functional cure) [2]. The enormous difficulties that
have been encountered in the quest of a cure for AIDS
reside in the complex virus/host interplay that is a hall-
mark of this disease. Infection with HIV is initially char-
acterized by a primary (acute) phase in which the virus
is partially controlled by a robust immune response of
the host [3]. Unfortunately, this immune response is not
sufficient to eradicate the virus from the body, opening
the way to the asymptomatic (chronic) phase. The
chronic phase is characterized by an initial “steady state”
between the virus and the immune system that is then
slowly tilted in favor of the former, eventually leading to
AIDS in the majority of the patients [4]. Treatment with
antiretroviral drugs (ART) can reproducibly decrease
viremia to levels below the limit of detection of the rou-
tine clinical assays and delays immune deterioration, but
is not sufficient to tackle the viral reservoirs or to induce
a strong immune response against the virus [5-7]. The* Correspondence: andrea.savarino@iss.it
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article, unless otherwise stated.viral reservoirs are formed early during acute infection
[8] and are exceptionally stable sources of viral persist-
ence [6,9], harboring latent copies of integrated virus
that are “invisible” to the immune system and unharmed
by ART (5,6,9, for a review on the latency mechanisms,
see: [10]). Viral reservoirs can be of both myeloid and
lymphoid lineage, allowing a widespread distribution to
different compartments such as the central nervous
system, the gut-associated lymphoid tissue and the re-
productive tract [11]. At a cellular level, central and
transitional memory T-cells (TCM and TTM) were re-
cently identified as a crucial source of viral persistence
during therapy [12]. Additionally, macrophages are
regarded as important contributors to this persistence,
as well [13].
This review provides an outline of the therapeutic suc-
cesses in the pathway towards a cure for AIDS. Our de-
scription is focused on the results that have so far been
obtained in humans or SIV/SHIV infected macaques,
which are, among the allowed animal models, those
phylogenetically nearest to humans and most closely re-
capitulating the pathogenesis of human AIDS [14,15].
Recent reports have provided substantial data supporting
the view that the path to a cure is a viable research av-
enue. These new data allow attempting a re-evaluation
of the paradigms that have oriented cure-related re-
search and addressing some of the questions that have
so far been left unanswered.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Acute infection offers an ideal time window for effective
therapeutic interventions [3]. A pioneering demonstra-
tion of the therapeutic potential of early treatment was
the case report of spontaneous control of viral replica-
tion following treatment interruption in the first “Berlin
Patient” [16] (not to be confused with Mr. Timothy
Brown, the second “Berlin Patient”, see next subchapter).
This man was treated during acute infection with a non-
standard ART regimen (containing hydroxyurea) and
subsequently underwent two structured treatment inter-
ruptions (STI). Eventually, after the second STI, the man
displayed a long-lasting (19 months, until he was lost to
follow-up) spontaneous control of viral load below the
assay detection limit (500 copies of viral RNA/mL).
Moreover, viral load control was accompanied by im-
mune restoration, with CD4 counts and CD4/CD8 ratio
progressively increasing over time [16]. This striking re-
sult confirmed those of a previous study by Vila et al.,
employing a similar drug regimen and achieving as well
a long-lasting post-therapy viral load control in two hu-
man subjects [17]. However, both studies were uncon-
trolled, and the two clinical cases described by Vila et al.
were associated with high CD4 counts and low viral
loads before treatment initiation [17]. A fully controlled
animal study employing a therapy containing hydroxy-
urea administered sequentially in the form of multiple
ART/STI cycles strengthened these case reports and
showed that post-therapy viral load control could be in-
duced in macaques acutely infected with the HIV homo-
log SIVmac251 [18]. Of note, in all these studies, apart
from the early treatment initiation, hydroxyurea may
have played a role in the post-therapy viral load control
obtained. Hydroxyurea exerts a cytostatic effect by inhi-
biting the activity of the ribonucleotide reductase en-
zyme, thus halting the cell cycle at the G1 phase [19].
This effect may hamper viral reservoir maintenance/ex-
pansion in TCM and TTM cells that mainly relies on
antigen-driven and homeostatic proliferation respectively
[12]. Despite these promising results, combinations of
hydroxyurea and antiretroviral drugs displayed in some
instances high pancreatic and hepatic toxicity [20,21]
and consequently hydroxyurea is not recommended for
routine treatment of HIV infection, although there is
still ongoing research on this topic [22].
Another uncommon ART regimen administered during
early infection yielded promising results in a recent study
conducted in macaques infected with different SIV/SHIV
strains [23]. In some of these animals, a prolonged (more
than 8 years) tenofovir monotherapy proved able to in-
duce a spontaneous control of the infection following the
final treatment withdrawal [23]. Apart from the early
treatment initiation, this result may be due to an effect
of tenofovir in selecting suboptimal drug resistancemutations, and the result may also have been contributed
by the additional interventions to which the macaques
were subjected during follow-up (temporary depletion of
CD8+ cells and treatment at viral rebound).
Treatment during acute infection has provided some
amount of clinical success also with more traditional ART
regimens [24-30]. News such as the case report of the cure
of an ostensibly HIV+ baby treated in the very early phase
of the disease [30] and, more importantly, the results of
the ANRS VISCONTI study [29] have been hailed with
widespread enthusiasm. Of particular note, up to ≈ 15% of
the early treated individuals have been shown to display
spontaneous control of viremia following STI [27]. How-
ever, the rate of post-therapy control following ART ad-
ministration during the acute phase may be lower (≈5%)
according to another report [28]. Moreover, no definite
timing and drug composition has been proven to reprodu-
cibly induce post-therapy control even in a minority of pa-
tients, and several studies have failed to induce any
significant reduction in the post-therapy viral set point fol-
lowing treatment during acute infection [31-33].
Despite these mixed results, the data available indicate
that ART administration during acute infection can in-
duce, in a minority of cases, a post-therapy control of the
infection which is independent from known favorable gen-
etic backgrounds [29] (Figure 1). Several hypotheses have
been postulated to explain the enhanced efficacy of ART
treatment during primary infection. The most frequently
cited explanations are: 1) the preservation of an efficient
immune response [34,35], 2) the induction of a “self-vac-
cination” after multiple STIs [16,18], and 3) the impair-
ment of viral reservoir formation [27,29,36-38]. A reduced
viral reservoir size does not per se guarantee successful
ART withdrawal [39], but is, even in the most conservative
scenario, a promising platform in the quest of a cure. The
overwhelming majority of HIV+ individuals, however, are
diagnosed during the chronic phase of the infection, and a
large body of evidence shows that STI protocols (even in
the form of short “drug holidays”) are not effective in im-
proving the course of the disease once the chronic phase
is established ([40-42], reviewed in: [43]).
Hit later, hit harder
The mainstream approach to purge the viral reservoirs
during chronic infection is a multi-step “shock and kill”
therapy [44]. During the “shock” phase, the latent virus
harbored in the reservoirs is expected to be pharmaco-
logically reactivated and prompted to resume productive
infection. During the”kill” phase, the newly produced vi-
rions would be blocked by ART, while the HIV-infected
cells are expected to be eliminated by viral cytopathoge-
nicity, or recognized and killed by the immune system. A
plethora of compounds have been put forward as candi-
dates to induce the “shock” phase (recently reviewed in:
Figure 1 ART administration during acute infection results in spontaneous control of viral load in a minority of individuals following
therapy suspension. The dotted line depicts representative viral load dynamics of patients controlling the infection following ART withdrawal, as
compared to non controllers (solid line). The upper limit of the percentage of controllers is taken from [27]).
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are histone deacetylase inhibitors (HDACI’s). Several
HDACI’s (e.g. valproic acid, vorinostat, panobinostat) have
been tested or are currently under investigation in both
pre-clinical studies and clinical trials (reviewed in: [47]).
Vorinostat [i.e. suberoylanilide hydroxamic acid (SAHA)]
was recently reported to have a moderate latency disrupt-
ing effect in a group of patients previously selected for the
responsiveness of their resting CD4+ memory T-cells to
treatment with this drug in vitro [48]. However, prelimin-
ary data do not show significant effects of vorinostat on
viral reservoir size [49,50], while no data on post-therapy
viral dynamics are available so far. Moreover, treatment
with combined ART/vorinostat regimens on SIVmac-
infected macaques led to mixed or disappointing results
[51,52]. More data on the in-vivo effects of vorinostat will
be available from the two ongoing clinical trials investigat-
ing the effects of this drug on individuals under ART
(NCT01319383, NCT01365065). For the remaining HDA-
CI’s only data obtained from cell cultures are available at
present [53-55], although panobinostat is currently under
investigation in a Phase I/II clinical trial (NCT01680094).
Another approach aimed at HIV reactivation from la-
tency involves the use of cytokines (reviewed in [56]). In
particular, the use of IL-7 in combination with ART intensi-
fication is currently being investigated (NCT01019551).
Unfortunately, in two recent clinical trials, the addition of
IL-7 to standard ART protocols did not result in viral re-
activation from latency [57], and increased the size of theviral reservoir [58], in line with the well-known effects of
this cytokine, favoring homeostatic proliferation of TCM
and TTM cells [12,58,59].
Despite the enormous efforts that have been put in the
study of HIV reactivating HDACI’s and cytokines, the
most promising results so far obtained in the quest of a
cure for AIDS are not derived from these approaches. The
most astonishing result in the field to date, and the first
proof of concept for the feasibility of a sterilizing cure dur-
ing chronic HIV infection, is the case report of the treat-
ment of Mr. Timothy Brown, the aforementioned second
“Berlin Patient” [60,61]. Apart from being chronically in-
fected with HIV, this man was diagnosed with acute mye-
loid leukemia and consequently treated with an aggressive
combination of ablative chemotherapy/radiotherapy, im-
mune suppression through drugs and allogeneic stem cell
transplantation. Importantly, the donor selected for the
transplantation was homozygous for the Δ32 deletion of
the CCR5 gene [60]. This gene encodes for the main core-
ceptor employed by HIV for entry into cells, and individ-
uals homozygous for the Δ32 deletion (about 1% of the
caucasian population) are protected from HIV infection
[62]. Following stem cell transplantation, Mr. Brown
stopped taking antiretroviral drugs, and has remained off-
ART since then, with no signs of disease progression
[60,61]. Of note, in spite of an extensive sampling through-
out the years, most of the analyses have failed to detect
HIV RNA or DNA in blood and tissues, and the HIV-
specific antibody titers have steadily decreased over time,
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achieved [61,63]. Despite the enormous excitement gener-
ated by the news of this cure, the scarcity of HLA-DR-
compatible CCR5 Δ32 donors makes it very difficult to rep-
licate the whole experiment. Consequently, several attempts
have been made to isolate the contribution of each of the
different therapy components. Allogeneic bone marrow
transplantation had been employed for treatment of HIV
since the first years of the epidemics (reviewed in [64]) and
had been even advocated as a possible curing strategy [65].
The most visible difference between these early attempts
and the treatment of Timothy Brown is the favorable gen-
etic background of the cells received by the latter, bearing
the homozygous CCR5 Δ32 deletion. Thus, it is not surpris-
ing that many investigators have used this observation as a
starting point for further studies. In this regard, a gene ther-
apy approach aimed at disrupting the CCR5 gene (virtually
recreating the Δ32 deletion) is currently under investigation
in clinical trials (NCT01252641, NCT00842634). In these
studies, the disruption of CCR5 is performed employing
zinc finger nucleases in previously isolated autologous cells
that are afterwards re-transplanted in the host. The prelim-
inary results released so far do not allow drawing a definite
conclusion on post-therapy viral load dynamics, which
seem to be quite variable among study subjects, although
post-therapy viral load containment may have been
achieved in a small subset of individuals that were heterozy-
gous for CCR5 Δ32 at baseline [66]. Anyway, the zinc finger
treated CD4+ T-cells have been shown to be able to persist
in the organism at least one year after the transplant and
have had an enhancing effect on CD4 counts in immuno-
logic non-responders [67].
On the other hand, recent data indicate that allogeneic
stem cell transplantation may possibly lead to a cure also in
the absence of the CCR5 Δ32 mutation. This is suggested
by the outcome of the treatment of two HIV+ individuals
(the “Boston patients”) that had received an allogeneic
transplantation of stem cells from CCR5 wild-type donors.
After transplantation, while still receiving ART, these indi-
viduals displayed a reduction of viral DNA in peripheral
blood to undetectable levels [68]. Further investigation
proved that viral DNA could not be detected with large
scale analysis in PBMCs and in rectal tissue, and thus STI
was attempted in both patients [69]. Following ART inter-
ruption, no viral rebound was observed, and, despite the
relatively short follow-up, the data available suggest that a
cure may have been achieved [69]. An important element
of the strategy employed for treating the “Boston patients”
may have been the long-term ART maintenance following
transplantation which may have blocked viral reseeding be-
fore the establishment of a full donor chimerism. This
aspect differentiates the “Boston patients” from the sec-
ond “Berlin patient” in which ART was discontinued
from the day of transplantation and viral reseeding waslikely hampered by the CCR5 Δ32 mutation of the trans-
planted cells. On the other hand, a common feature be-
tween these case reports is that the “Berlin patient” and
the two “Boston patients” were all heterozygous for CCR5
Δ32 before transplantation [60,68] (see Figure 2). Al-
though their blood cells were fully replaced afterwards (by
homozygous CCR5 Δ32 cells in the “Berlin patient” and by
wild type CCR5 cells in the “Boston patients”), it cannot
so far be excluded that their original CCR5 Δ32 heterozy-
gous status may have played a role in the clinical outcome.
It is known that heterozygosity for CCR5 Δ32 is associated
with slower disease progression [62,70] and the results of a
recent study conducted in non-human primates suggest
that CCR5 expression levels may be associated with the
size of the viral reservoir [71]. Despite the necessity of con-
ducting further studies on this topic, the high treatment-
related mortality of allogeneic transplant [72] hampers the
use of this technique as an HIV curing strategy, unless sal-
vage therapies are required due to life-threatening co-
morbidities. On the whole, the studies hereto reviewed
support the hypothesis that decreasing the viral reservoir
size through drugs, coupled to immune system renovation,
may be a key to the achievement of a cure.
Turning back time
From the aforementioned studies, it is evident that the
therapies that have resulted in a cure during the chronic
phase of the infection bear a much higher degree of risk as
compared to the strategies adopted in the acute phase.
Thus, the possibility of inducing an acute infection-like
scenario in an advanced stage of the disease may represent
a unique option to open a new window of opportunity for
the therapeutic interventions adopted during the acute
phase. A good candidate for this strategy is the gold-based
compound auranofin [52] which has been employed for
many years in treatment of rheumatoid arthritis [73]. Our
group has recently shown the potential of auranofin to act
as an anti-reservoir compound in vivo when administered
to chronically-SIVmac251 infected macaques [52]. Of
note, auranofin is able to preferentially induce differenti-
ation/cell death of the memory T-cell compartment in-
cluding the TCM and TTM CD4
+ cells which encompass
the main viral reservoir [52] (for a schematic representa-
tion of the mechanism of action of auranofin, see Figure 3).
Beside its anti-reservoir effect, the addition of auranofin
to ART was able to prompt a drastic modification of the
post-therapy viral load dynamics in chronically SIVmac251-
infected macaques [52,74]. Following treatment interrup-
tion, the macaques that had received the ART/auranofin
combination displayed a sharp viral load rebound reminis-
cent of an acute infection peak which was in turn accom-
panied by an increase in specific immune responses in
accordance with the typical acute infection scenario [3,74].
From a therapeutic perspective, treatment with ART/
Figure 2 Schematic representation of the therapeutic interventions received by the second “Berlin patient” and the “Boston patients”.
Although the second “Berlin patient” had received two stem cell transplants, only one is shown for clarity purposes. Note that the length of the arrows
indicating the period under ART is meant to provide a qualitative comparison between the ART and transplantation schedules and is not in scale.
Figure 3 Treatment with auranofin increases the turnover of CD4+ T-cell subsets and induces a partially selective apoptosis of the
memory compartment. The cell subsets are identified by the expression of the surface markers CD28 and CD95 (naïve: CD28+ CD95-; central
and transitional memory: CD28+ CD95+; effector memory: CD28- CD95+).
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point (≈1 Log10 viral RNA copies/mL of plasma) [52] and,
importantly, treatment during the acute infection-like viral
rebound showed the potential to mimic the aforementioned
effects of early ART administration [74]. Indeed a short
cycle of ART during the acute infection-like peak induced a
further reduction in post-therapy viral load set-point [74]
and, despite being attempted in a low number of macaques
(n = 2), would prove effective in the long-term follow-up
[74]. The viral load control induced with this therapeutic
protocol may have been contributed to by the previous res-
ervoir reduction prompted by auranofin and by the use of
an ART regimen containing maraviroc, which, by blocking
CCR5, may inhibit antigen-driven proliferation of the viral
reservoir [74]. Although the mechanism behind the drastic
modification of the viral rebound pattern induced by aura-
nofin remains partially unclear, its effects on the macaque
AIDS model suggest that this drug may offer an attractive
possibility of successfully applying, to the chronic phase of
the infection, strategies that would have been effective only
in the early stages.Immune enhancement: rejuvenating the immune system?
Enormous efforts have been put in the development of
strategies able to boost antibody and/or cell-mediated im-
mune responses against HIV (reviewed in [75]). The cura-
tive potential of broad and robust cell-mediated immune
responses, in particular by CD8+ T-cells, is suggested by
the association of such responses with better disease pro-
gression resulting in spontaneous drug-free control of viral
load in a minority of individuals [76-79]. Thus, drugs able
to bolster immunity against HIV-infected cells could repre-
sent an ideal tool for prompting, or supporting, a spontan-
eous control of the infection [75]. A promising compound
for enhancing cell-mediated immune responses against
HIV may be buthionine sulfoximine (BSO), a glutathione-
depleting agent previously tested for cancer treatment in
phase I clinical trials [80]. We recently showed that the
addition of BSO to the aforementioned ART/auranofin
combination is able to promote a significant and long-
lasting enhancement of specific immune responses di-
rected against SIVmac Gag [81]. Boosting immunity
against Gag is an attractive achievement because several
studies have shown that strong anti-Gag immune re-
sponses are associated with low viral loads and high CD4
counts both in macaques and humans [82-86]. Moreover,
the results of a recent study suggest that CD8+ T-cells may
reduce the viral reservoir by recognizing Gag antigens pro-
duced by latently infected resting CD4+ T-cells [87]. In ac-
cordance with these studies, enhancement of the immune
responses against Gag following suspension of treatment
with ART/auranofin/BSO was associated with the obtain-
ment of a functional cure-like condition in a studyconducted on a small number of chronically SIVmac251-
infected macaques [81].
Partially similar results were obtained using a therapeutic
vaccine based on dendritic cells pulsed with whole inacti-
vated virus [88-91]. This vaccine proved able to achieve
drug-free control of viral load in a subset of chronically
SIVmac251-infected macaques [88] and to induce a reduc-
tion of viral load, although moderate, in ART-naïve HIV+
subjects [89,90]. Moreover, coupling the vaccine adminis-
tration to ART induced a reduction in post-therapy viral
load set point in some individuals [91]. Of note, the high-
est viral load reductions observed in ART-naïve subjects
were associated with high numbers of Gag-specific CD8+
T-cells [89].
A proof-of-concept that strong CD8+ (in particular
TEM)-mediated immune responses can even lead to viral
eradication was recently furnished by a preventive vaccine
study conducted on macaques challenged with SIVmac239
[92]. Despite all vaccinated macaques becoming infected
following multiple challenges with the virus [93], about half
of them proved able to spontaneously control the infection
and, strikingly, to get rid of the virus completely in the long
run [92]. Interestingly, an involvement of TEM cells was
also shown, by multiple correlation analysis, in the effects
of the auranofin-based therapeutic approach [52].
On the other hand, antibody-mediated immune re-
sponses have also proven the ability of inducing post-
therapy viral load control [94,95]. In particular, in the
recent study of Barouch et al., a cohort of SHIV(env)-in-
fected macaques was treated with wide spectrum neutraliz-
ing antibodies [95]. This treatment produced a functional
cure in those macaques starting from viral loads of less than
3.5 Log10 viral RNA copies/mL of plasma [95]. Of note, this
experiment provides an artificial substitution of a “non-
functional” immune system with a surrogate functional im-
munity, i.e. the passive antibody transfer. The capability of
adoptive antibody transfer to induce a functional cure only
in those macaques displaying low baseline viral set points,
supports the view that a limited viral reservoir should ac-
company the immune system renovation.
Finally, also the effects of transplantation strategies on
viral load control may be associated with enhancement of
immune responses. A study by Villinger et al. conducted
in chronically SIVmac239-infected macaques showed that
adoptive transfer of activated autologous CD4+ T-cells
may result in spontaneous post-therapy control of the in-
fection [96]. This approach can hardly be employed in
humans since it requires cells isolated before the infection,
but it suggests that renovation of the immune system is
important for obtaining effective immune responses [96].
Of note, autologous stem cell transplantation did not re-
sult in a cure of HIV+ individuals [97], suggesting that cells
isolated following infection may not be apt to prompt im-
mune enhancement. Instead, the likely cures observed
Table 1 Summary of the main characteristics of the therapeutic strategies described in this review
Notable Results Stage Safety Scalability
ART during acute infection Long-term post-therapy viral load control in a
minority of individuals [16,17,23-30].
Clinical/pre-clinical High
Low (few patients are detected
HIV+ at acute infection)
Viral reactivation with HDACI’s Possible disruption of latency [48,49,53-55].
No viral reservoir reduction [49].
Clinical/pre-clinical Medium High
Viral reactivation with cytokines IL-7 might disrupt latency but replenishes
the viral reservoir [57-59].
Clinical Medium Medium/high
Gene therapy for disruption
of CCR5
Mixed impact on viral load (depending on the genetic
background) [66]. Possible immunologic improvement [67].
Clinical Medium (long-term effects unknown) Very low
Allogeneic stem cell transplant Likely sterilizing cures in the second “Berlin Patient”
[60,61,63] and in the “Boston Patients” [68,69].
Clinical Very low Very low
Addition of auranofin and BSO to ART Long-term post-therapy control in chronically
SIVmac251 infected macaques [74,81].
Late pre-clinical
Medium/high (good safety profile
for individual drugs in humans)
High
Therapeutic vaccine with whole
virus-pulsed dendritic cells
Post-therapy viral load control in a subset of macaques [88].
Viral load and viral load set-point reduction in a subset of




Long-term post-therapy control in chronically
SHIV(env) infected macaques starting from
low viral loads [95]
Late pre-clinical High High
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tients” [69] may have been induced or facilitated by the
strong immune responses resulting from graft versus
host disease, exacerbated by a partial HLA donor/re-
ceiver mismatch in one of the two patients, which may
have played a critical role for the elimination of the viral
reservoirs [68].
Conclusions
The studies reviewed herein indicate that curing, and even
eradicating primate lentiviruses, including HIV-1, could be
possible, at least in certain cases (see Table 1). However, it
is important to point out that the majority of the “func-
tional” cures that have so far been reported have been ob-
tained during the acute phase or a short time thereafter, i.e.
at a time in which the viral reservoir and the immune dam-
age are still limited. The design of future therapeutic strat-
egies should address the chronic phase of the disease,
affecting the large majority of the HIV+ individuals. The
most successful approaches tested so far, though still pre-
liminary and/or based on a small number of cases, strongly
suggest that the path to a cure involves two key players:
the viral reservoir and the immune system. In the typical
scenario of chronic infection with an average/large viral
reservoir and an impaired immune system, some of the ap-
proaches that have been successful showed the ability to
target both the viral reservoir and the immune system
through gradual (auranofin) or abrupt (chemotherapy/allo-
geneic transplant) immune system renovation, followed by
enhanced immune responses either against conserved viral
antigens (auranofin + BSO) or the host’s infected cells (graft
versus host disease). In this regard, further studies, fully
controlled and with larger number of subjects, will be re-
quired to assess the curative potential of the aforemen-
tioned strategies. The ultimate goal will be to obtain with
scalable drug combinations, the cure that has been induced
with more aggressive approaches.
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